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(S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], (S)-9-(3-hydroxy-2-phosphonylmeth-
oxypropyl)-2,6-diaminopurine [(S)-HPMPDAP], cyclic (S)-HPMPA [(S)-cHPMPA], 9-(2-phosphonylmethoxy-
ethoxyethyl)-2,6-diaminopurine (PMEDAP), and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-
HPMPC] were examined for their inhibitory effects on Epstein-Barr virus (EBV) replication. The 50% effective
concentrations for inhibition of viral DNA replication were 0.16, 0.03, 2.0, 1.5, and 0.08 ,uM for PMEDAP,
(S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and (S)-HPMPA, respectively. The relative efficacies based on the
in vitro therapeutic index was (S)-HPMPC (5,000) > PMEDAP (1,000) = (S)-HPMPA (1,000) > (S)-cHPMPA
(136) > (S)-HPMPDAP (78). Certain ratios of combinations of (S)-HPMPC with 3'-azido-3'-deoxythymidine
produced a synergistic inhibitory effect on EBV genome replication, but others exhibited an antagonistic effect.
These results indicate that this series of acyclic nucleoside phosphonate analogs, and in particular (S)-HPMPC,
are potent and selective anti-EBV agents in vitro.
A new class of adenine analogs, with (S)-9-(3-hydroxy-2-
phosphonylmethoxpropyl)adenine [(S)-HPMPA] as the pro-
totype, has potent and selective activity against a broad
spectrum ofDNA viruses, including, in some cases, Epstein-
Barr virus (EBV) (4, 7). (S)-HPMPA and its close congener
9-(2-phosphonylmethoxyethyl)adenine (PMEA), but not (S)-
9-(2,3-dihydroxypropyl)adenine, are potent inhibitors of
EBV replication (7). The new acyclic nucleoside phospho-
nate analogs (5) that have been synthesized recently {(S)-9-
(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diamino-purine
[(S)-HPMPDAP], (S)-1-(3-hydroxy-2-phosphonyl-methoxy-
propyl)cytosine [(S)-HPMPC], cyclic (S)-HPMPA [(S)-cHP-
MPA], and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopu-
rine (PMEDAP)} provide the opportunity to evaluate the
structure-activity relationships involved in the inhibition of
EBV replication, disclose aspects of the molecular mecha-
nisms underlying anti-EBV activity, and guide the further
development of new antiviral drugs.
To determine the effects of the drugs on EBV DNA
replication, exponentially growing P3HR-1(LS) cells were
treated for 14 days with various concentrations of the drugs.
The cells were harvested, and the EBV genome copy num-
bers were determined (9). Table 1 shows the concentration-
dependent inhibition of EBV genome replication by
PMEDAP, (S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and
(S)-HPMPA. All these compounds strongly inhibited EBV
replication in a concentration-dependent manner. The num-
ber of EBV genome copies per cell decreased with increas-
ing drug concentrations in all cases, but with different
slopes.
We monitored cell growth and viability during treatment.
At a drug concentration of 10 ,uM, in comparison with the
control, there was an approximately 23% reduction in cell
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number with all drugs tested. At a drug concentration of 100
,uM, a further reduction (33 to 45%) in cell pumber was
observed. However, cell viability was not significantly af-
fected at a drug concentration of S ,uM an4 was only slightly
reduced at a drug concentration of 10 ,uM.
The 50% effective concentration for virus inhibition (EC50)
was determined from t!he semilogarithmic plot of drug con-
centrations against the nurpber of viral genome copies per
cell, assuming the residual genome level (30 copies per cell)
achieved by an effective drug concentration (5 to 100 ,uM,
depending on the individual drug) as! 0% and the viral
genome level in the controls with'po drug as 100% (9). We
have shown previously (9) that the residual EBV copy
number of 30 per cell is due to episomal forms, which are
insensitive to nucleoside analogs. The EC50s thus obtained
from the plots were 0.16, 0.03, 2.0, 1.5, and 0.08 FiM for
PMEDAP, (S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and
(S)-HPMPA, respectively (Table 2). Similarly, the EC90s
were 1.85, 1.76, 9.0, 7.0, and 3.42 jiM for PMEDAP,
(S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and (S)-
HPMPA, respectively. The values obtained from analysis of
the data by using the Concentration-Effect Analysis Program
(3) were in close agreement with those obtained by the
graphical method (9). As shown in Table 2, the relative
efficacy of the compounds based on their therapeutic index
(EC50/IC50, where IC50 is the 50% inhibitory concentration
for cell growth) was (S)-HPMPC (5,000) > PMEDAP (1,000)
= (S)-HPMPA (1,000) > (S)-cHPMPA (136) > (S)-HPMP
DAP (78).
The anti-EBV activities of these compounds appeared to
be selective, in that they all inhibited virus replication at
drug concentrations which were not significantly cytotoxic
or cytostatic in vitro. Despite the effective inhibition of the
production of linear forms of EBV DNA, which are repli-
cated by a virus-specified DNA polymerase (8), these drugs
had no effect on the EBV episomal forms of DNA (approx-
imately 30 copies per cell in the productive cell line P3HR-1
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TABLE 1. Concentration-dependent inhibition by PMEDAP,
(S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and (S)-HPMPA of
replication of EBV genomes
Concn Viability No. of EBVDrug(>M) (%B)a copies/cell'

























Control 0.0 87 600
a Cell viability was determined after the cells were grown for 4 days.
b Virus-producing cells, P3HR-1(LS), were exposed to various concentra-
tions of drug for 14 days, and the nuniber of EBV genome copies per cell was
determined by EBV-specific DNA-DNA hybridization. Results were the
average of two separate experiments with triplicate determinations. ND, not
determined because of a cytostatic effect.
(LS) and 60 copies per cell in non-virus-producing Raji
cells), which are presumed to be replicated by host DNA
polymerase.
Since (S)-HPMPC was the most potent drug among the
series of analogs tested, we decided to determine the kinetics
of inhibition and reversibility of (S)-HPMPC in parallel with
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU). Figure 1 indi-
cates that for both drugs, 14 days of drug treatment was
needed to reduce the viral genome copy numbers (30 copies
per cell) to the residual level because of EBV episomes.







DAY 0 5 10 14 5 12 19
DRUG - + + + - - -
FIG. 1. Kinetics of inhibition and reversibility of EBV DNA
replication in P3HR-1 (LS) cells treated with 10-fold the EC90 of
(S)-HPMPC (18 ,uM) or BVdU (50 ,M). Values are means +
standard deviations for two separate experiments with triplicate
determin,ations. (S)-HPMPC-treated cells exhibited a significantly
slower kinetics of reversibility than BVdU-treated cells did (P <
0.001). The results of Fig. 1 were the average of two separate
experiments with triplicate determinations. The data were statisti-
cally analyzed by using the two-way analysis of variance for
randomized blocks (14).
genome copy numbers than BVdU did. Upon removal of
BVdU, the number of viral genome copies per cell remained
at low levels (18% of the control level) for 12 days, becoming
gradually restored to 38% of the control level by 19 days.
(S)-HPMPC-treated cells exhibited a significantly slower
kinetics of reversibility than BVdU-treated cells did (P c
0.001). The viral genome numbers were restored to 15% of
the control level by 12 days. After 19 days of drug removal,
the viral genome copies per cell remained at a low level,
approximately 26% of the control level.
To assess whether the combination of 3'-azido-3'-deoxy-
thymidine (AZT) and (S)-HPMPC may have a synergistic
effect on the inhibition of EBV genome replication, we
treated P3HR-1(LS) cells with various combinations of the
two drugs as well as with each drug alone. The effects on
EBV genome copy numbers were determined after 14 days
of treatment (Table 3). For example, the combined effect of
0.1 ,uM (S)-HPMPC plus 1 ,uM AZT (EBV genome copy
numbers at 27% of the control level) was greater than that of
0.1 ,uM (S)-HPMPC alone (32% of control) or 1 ,uM AZT
alone (67% of control). The analysis of the data for (S)-
HPMPC alone and for AZT alone by the median-effect plot
resulted in linear correlation coefficients (r) of 0.976 and
0.998, respectively. On the basis of the numbers of EBV
genome copies, the two drugs were evaluated for synergy by
applying the multiple drug effect analysis. Synergy calcula-
tions were performed for all datum points that resulted in
less than 99% inhibition by combination indices (CIs) (Table
TABLE 2. Inhibitory effects of PMEDAP, (S)-HPMPC, (S)-HPMPDAP, (S)-cHPMPA, and (S)-HPMPA on cell growth
and EBV replication
Drug IC50 (LM) EC50 (~LM)a EC90 (iM)' IC50/EC50
PMEDAP 160 0.16 (0.154) 1.85 (2.73) 1,000
(S)-HPMPC 150 0.03 (0.0314) 1.76 (1.89) 5,000
(S)-HPMPDAP 155 2.0 (2.197) 9.0 (9.46) 78
(S)-cHPMPA 150 1.5 (1.94) 7.0 (7.64) 136
(S)-HPMPA 80 0.08 (0.09) 3.42 (3.78) 1,000
a Values in parentheses were determined by using the dose-effect analysis program of Chou and Chou (3), as described in the text.
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TABLE 3. CIs for combined effects of AZT and (S)-HPMPC on EBV genome copy numbers in P3HR-1(LS) cells
(S)-HPMPC AZT concn a Concn No. of EBV Fraction cie
concn (>tM) (AM) Rati(oM)b genome fecteda=1copies/cell' affected"
O 0 445
0 1 300 0.326
0 5 150 0.663
0 10 110 0.753
0.1 0 140 0.685
1.0 0 80 0.820
5.0 0 30 0.933
0.1 1 1:10 1.1 120 0.730 0.63 0.69
1.0 1 1:1 2.0 65 0.854 1.01 1.06
5.0 1 1:0.2 6.0 30 0.933 0.76 0.77
0.1 5 1:50 5.1 125 0.719 1.23 1.61
1.0 5 1:5 6.0 62 0.861 1.07 1.26
5.0 5 1:1 10 28 0.937 0.72 0.77
0.1 10 1:100 10.1 114 0.744 1.56 2.06
1.0 10 1:10 11 60 0.865 1.22 1.56
5.0 10 1:2 15 25 0.944 0.62 0.69
a Molar ratio of (S)-HPMPC and AZT in the mixture.
bSum of the concentrations of (S)-HPMPC and AZT.
c The numbers of EBV genome copies per cell were determined by EBV-specific DNA-DNA hybridization.
d The fraction affected for EBV genome copies per cell was calculated as [1 - (EBV genome copy numbers of drug-treated culture/EBV genome copy numbers
of no-drug culture)].
CIs were calculated as described previously (1, 2); the values are for the mutually exclusive drug effect (a = 0) and for mutually nonexclusive effect (a = 1).
3) and by a classical isobologram (data not shown) con-
structed from the data. As seen in Table 3, four of nine
combinations [ratio of (S)-HPMPC:AZT, 1:10, 1:0.2, 1:1,
and 1:2] showed synergistic inhibitory effects (CI < 1) on
EBV genome replication, and the other five ratios produced
antagonistic effects (CI> 1). The equipotency ratio based on
the EC50s for (S)-HPMPC (0.03 ,uM) and AZT (2.38 ,uM) was
1:79. There appeared to be no specific ratio which tended to
favor synergism. Furthermore, the (S)-HPMPC and AZT
effects, whether they were mutually exclusive (a = 0) or
mutually nonexclusive (a = 1), yielded similar CIs and, thus,
similar degrees of synergism or antagonism.
The molecular basis for the differences in the anti-EBV
activities of these compounds is not known. The present
results indicate that substitution of the 9-(2-phosphonyl-
methoxyethyl) group in PMEDAP by a 9-(3-hydroxy-2-
phosphonylmethoxypropyl) group, as in (S)-HPMPDAP,
results in a 13-fold decrease in anti-EBV potency. Similarly,
when the 2-amino group of PMEDAP is substituted by a
hydrogen, as in PMEA (EC50 = 1.1 ,uM, according to our
previously published data [7]), a sevenfold reduction in
anti-EBV activity was observed. Interestingly, substitution
of the 2-amino group of (S)-HPMPDAP by a hydrogen, as in
(S)-HPMPA, resulted in a 25-fold increase in anti-EBV
activity [EC50 for (S)-HPMPA, 0.08 ,uM]. With the purine
ring remaining intact, replacement of the linear 3-hydroxy-
2-phosphonylmethoxypropyl side chain of (S)-HPMPA by a
cyclic phosphonylmethoxyethyl group, as in (S)-cHPMPA,
resulted in an approximately 19-fold decrease in potency.
Furthermore, with the 3-hydroxy-2-phosphonylmethoxpro-
pyl side chain unchanged, substitution of cytosine, as in
(S)-HPMPC, for adenine, as in (S)-HPMPA, gave an almost
threefold increase in anti-EBV activity. (S)-HPMPC thus
emerged as the most potent EBV inhibitor of the compounds
examined here.
In studies of the structure-activity relation of acyclic
pyrimidine nucleosides (2), we have found that modifications
in the pyrimidine ring influence the selective activity against
EBV. Furthermore, studies with acyclic adenosine analogs
have indicated that modification of the 2,3-dihydroxypropyl
of (S)-9-(2,3-dihydroxypropyl)adenine to 2-phosphonylmeth-
oxyethyl, as in PMEA, or 3-hydroxy-2-phosphonylmethoxy-
propyl, as in (S)-HPMPA, significantly enhances antiviral
activity (7).
This series of acyclic nucleoside phosphonate analogs
containing a phosphorus atom attached via a P-C bond were
designed such that hydrolysis by phosphomonoesterases
could be prevented. The ether linkage between the alkyl
residue and the phosphonylmethyl group cannot be metab-
olized to phosphonoacetate or phosphonoformate, which is
known to inhibit human immunodeficiency virus (HIV) (12);
further evidence for this lack of metabolism stems from the
activity of (S)-HPMPA against two DNA polymerase mu-
tants of herpes simplex virus type 1 that are resistant to
phosphonoacetate (4). In addition, antiviral activity resides
primarily with the (S)-enantiomer, which means that the
antiviral activity of the compound is based on its chirality.
Also, the drugs are not thought to interact with S-adenosyl-
homocysteine hydrolase (4), be degraded by deaminases
(11), or require phosphorylation by a virus-specified thymi-
dine (deoxycytidine) kinase (TK) for activity. An important
feature that may have therapeutic implications is the long-
lasting antiviral effect of (S)-HPMPC, as observed in revers-
ibility experiments (Fig. 1). (S)-HPMPC, (S)-HPMPA, and
their congeners may be taken up by the cells in their native
form, since they cannot be enzymatically dephosphorylated,
and this may account for the longer activity against EBV
replication.
Several different ratios of combinations of AZT with
(S)-HPMPC were found to have synergistic inhibitory effects
on EBV genome replication, whereas some ratios exhibited
an antagonistic effect. Previously, we reported (10) that
combinations of interferon alpha, interferon gamma, and
AZT are also synergistic in preventing cellular microfocus
formation of EBV-infected umbilical cord blood lympho-
cytes. These results have implications for the treatment of
EBV-induced lymphoproliferation. Here we presented indi-
cations that some combination of drugs may also be syner-
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gistic, although not strikingly so, in inhibiting EBV replica-
tion itself. These results may provide a lead to the further
development and use of drug combinations that may produce
fewer side effects through lower dosages and a reduced
likelihood of emergence of drug-resistant virus strains.
Our previous findings (13) indicated that some of the
acyclic nucleoside phosphonate analogs (i.e., PMEA) are
quite effective against HIV replication in cell cultures (13).
EBV has been suggested as one of the cofactors which
determines whether HIV infection leads to AIDS (6). Since
opportunistic virus infections, in particular herpesvirus
(EBV, herpes simplex virus, varicella zoster virus, human
cytomegalovirus, and human herpesvirus 6) infections, are
prevalent in patients with AIDS (1, 15), the broad-spectrum
activities of these series of compounds may be of additional
benefit if the compounds are used in the treatment of patients
with AIDS.
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